Volume 27, Number 11—November 2021
Dispatch
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Figure 1

Figure 1. Vaccine doses among adolescents and total severe acute respiratory syndrome coronavirus 2 infections, Israel, June 1–August 26, 2021. A) Daily frequency of administration of first and second dose of BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com) among adolescents 12–15 years of age. B) Daily cases of severe acute respiratory syndrome coronavirus 2 infection in persons of all ages.
Page created: September 23, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.